This module examines the later stages of diabetic kidney disease (DKD), including how it may affect a person’s general health and diabetes control, and what efforts should be made to prevent or delay its progression.
Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatinr MS on behalf of the DECLARE_TIMI 58 Investigators. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2019;380(4):347-357.
http://pubmed.ncbi.nlm.nih.gov/30415602
Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chur PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW; CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019 Jun; 380:2295–2306.
https://www.ncbi.nlm.nih.gov/pubmed/30990260
By the end of this module, you will be able to:
✓ Explain current and future strategies for people in the later stages of diabetic kidney disease (DKD) to prevent, delay and manage their condition
✓ Identify possible roles for SGLT-2 inhibitors for the treatment of DKD emerging from clinical trial results
✓ Develop management plans for people with diabetes and DKD to prevent, delay or manage their condition. including in the later stages of DKD
This module includes self-marked assessments, such as knowledge checks and/or case studies, as well as a marked final assessment, which you can attempt up to five times. To complete the module, you must review all chapters, pass the final assessment (80% pass mark), and fill in our feedback form.